Diary - News All news PDC*line Pharma raises €20 million in Series B financing round

PDC*line Pharma raises €20 million in Series B financing round

Funding includes €13.9M in equity and €6.1M in grants; will support company’s
phase I/II trial with PDC*lung01 candidate in lung cancer

Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. The company has raised a total of €20 million ($22.2M).

Two and a half years after its last round of fundraising in July 2017, PDC*line Pharma has attracted new investors, securing a further capital increase of €13.9M ($15.5M). In addition, the company will receive €6.1M ($6.8M) in loans and subsidies from the Walloon Region of Belgium, which has backed the company since it expanded its operations there in 2016.